

Annual Meeting SVGGO/ASCO 2026

01. October 2026, Inselspital Bern

08:40	Registration
09:00	Welcome from SVGGO president
09:05	Opening lecture FRAX: Update and Clinical Implications <i>John Kanis, University of Sheffield, United Kingdom</i>
09:45	Selected short communications (9 min presentation + 3 min discussion) 09:45 Early rebound effect under denosumab treatment: description and implications for practice, <i>Charlotte Leyvraz</i> 09:57 Risk of Multiple Lower Extremity Fractures in Methotrexate-Treated Patients: Evidence for ‘Methotrexate Osteopathy’?, <i>Elias Bührer</i> 10:09 A sex-stratified pilot study on renal osteodystrophy and antiresorptive effects in the BXD consortium of recombinant inbred mice, <i>Yunsu Jang</i>
10:20	Coffee break
10:45	Clinical Session: Fracture Risk and Outcomes – Revisiting risk factors for fractures in primary and secondary prevention, <i>Judith Everts</i> – Summary of DO-HEALTH trial results on bone and muscle outcomes, <i>Melanie Kistler-Fischbacher</i>
11:25	Industry Symposium (Labatec) - ABL as a new therapeutic option for high-risk patients (<i>Labatec</i>)
12:10	State of the Art Updated SVGGO guidelines, <i>Christian Meier</i>
12:30	Lunch 12:30-13:00 General assembly SGBOND 12:30-13:00 General assembly SVGGO/ASCO
13:30	Rare Bone Diseases Symposium - Pyrophosphate: A new player in ectopic calcifications, <i>Georges Leftheriotis, Nice University, France</i> - Extraosseous calcification and ossification, <i>Elena Gonzalez-Rodriguez</i> - Pain in rare bone diseases: current understanding and knowledge gaps, <i>Mélanie Legrand</i>
14:40	STRONG Trial RCT on whey protein and exercise on fall and functional outcomes, <i>Heike A. Bischoff-Ferrari</i>
15:00	Coffee break

15:20	Selected short communications (9 min presentation + 3 min discussion) 15:20 Impact of FRAXplus adjustments versus FRAX on Fracture Risk Classification in the Swiss Osteoporosis Registry, <i>Carla Martignongi</i> 15:32 Prediction of Therapeutic Response to Osteoporosis Treatment Using Clinical Data and Machine Learning, <i>Magdalena Hardegger</i> 15:44 Predictors of Anti-Osteoporotic Treatment After Fracture: A Nationwide Swiss Health Claims Study, <i>Judith Everts-Graber</i> 15:56 Site characteristics and patient selection criteria for romosozumab in routine clinical practice: insights from the PRIME European multi-country study, <i>Alireza Moayyeri</i> 16:08 Evaluating the clinical and economic impact of coordinated post-fracture care in osteoporosis management in Switzerland, <i>Judith Everts-Graber</i>
16:20	Symposium 3: Osteoporosis Treatment response Determinants of treatment response in osteoporosis: does lifestyle matter? <i>Emmanuel Biver</i>
16:40	Awards ceremony
16:50	End of the meeting

AMGEN

S A N D O Z

KYOWA KIRIN


GEDEON RICHTER

ALEXION[®]
AstraZeneca Rare Disease

 Inspired by **patients**.
Driven by **science**.


LABORATOIRES
Pierre Fabre
Primary Care

ascendis
pharma 

accord
We make it better

 **LABATEC**
— Valuing People. Science. Life —